Study Evaluating the Effect of IMA-026 on Allergen-Induced Late Asthma Response in Mild Asthma
NCT00725582
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
1. Healthy men and women 18 to 60 yrs with mild allergic asthma
2. only asthma med is short-acting bronchodilator used not more than twice weekly
3. FEV1 greater than 70% predicted and a demonstrated baseline late response to allergen induction
1. Upper respiratory infection or asthma exacerbation with 4 weeks of screening
2. Serious infection requiring parenteral antibiotics or hospitalization with 4 weeks of
test article administration
3. Positive radiographic findings indicative of respiratory disease other than asthma
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Huntington Beach, California
- Mission Viejo, California
- San Diego, California
- Wheat Ridge, Colorado
- Coeur d'Alene, Idaho
- Normal, Illinois
- South Bend, Indiana
- Baltimore, Maryland
- North Dartmouth, Massachusetts
- North Dartmouth, Massachusetts
- Minneapolis, Minnesota
- Bellevue, Nebraska
- Boys Town, Nebraska
- Omaha, Nebraska
- Winston-Salem, North Carolina
- Oklahoma City, Oklahoma
- Charleston, South Carolina
- Easely, South Carolina
- Dallas, Texas
- Seattle, Washington
- Tacoma, Washington
- Juiz de Fora,
- Porto Alegre,
- Porto Alegre,
- Porto Alegre,
- Rio de Janeiro - RJ,
- Beijing,
- Beijing,
- Beijing,
- Beijing,
- Changsha,
- Chengdu,
- Chengdu,
- Chongqing,
- Guangzhou,
- Kunming,
- Qingdao,
- Shanghai,
- Shenyang,
- Shenyang,
- Xi'An,
- Guatelama City,
- Guatelmala city,
- Guatelmala City,
- Guatemala City,
- Guatemala city,
- Banglore,
- Chennai,
- Coimbatore,
- Coimbatore,
- Hyderabad,
- Jaipur,
- Nagpur,
- Pune,
- Pune,
- Adachi-ku, Tokyo,
- Ako, Hyogo,
- Chiyoda-ku, Tokyo,
- Chuo-ku, Tokyo,
- Chuo-ku, Tokyo,
- Fujioka, Gunma,
- Himeji, Hyogo,
- Hitachi, Ibaraki,
- Iwamizawa, Hokkaido,
- Kanazawa, Ishikawa,
- Kitakami, Iwate,
- Kitakami, Iwate,
- Koga, Ibaraki,
- Koganei, Tokyo,
- Komaki, Aichi,
- Kunitachi, Tokyo,
- Mito, Ibaraki,
- Osaka, Osaka,
- Ota-ku, Tokyo,
- Sapporo, Hokkaido,
- Sendai, Miyagi,
- Sendai, Miyagi,
- Setagaya-ku, Tokyo,
- Takasaki, Gunma,
- Tomakomai, Hokkaido,
- Toshima-ku, Tokyo,
- Toshima-ku, Tokyo,
- Yao, Osaka,
- Yokohama, Kanagawa,
- Yokohama, Kanagawa,
- Daugavpils,
- Preili,
- Riga,
- Riga,
- Riga,
- Riga,
- Riga,
- Riga,
- Ventspils,
- Monterrey,
- Zapopan,
- Zona Río,
- Callao,
- Lima,
- Lima,
- Krakow,
- Lodz,
- Lodz,
- Ostrow Wielkopolska,
- Poznan,
- Tczew,
- Gatchina (Leningradskaya oblast),
- Moscow,
- Moscow,
- Moscow,
- Moscow,
- St. Petersburg,
- St. Petersburg,
- St. Petersburg,
- Los Angeles, California
- Stockton, California
- Centennial, Colorado
- Denver, Colorado
- Panama City, Florida
- Winter Park, Florida
- Novi, Michigan
- Plymouth, Minnesota
- St. Louis, Missouri
- Bozeman, Montana
- Skillman, New Jersey
- Raleigh, North Carolina
- Cincinnati, Ohio
- Portland, Oregon
- Greenville, South Carolina
- Union, South Carolina
- El Paso, Texas
- San Antonio, Texas
- Florianopolis,
- Porto Alegre,
- Sao Paulo,
- Sao Paulo,
- Chengdu,
- Chongqing,
- Guangzhou,
- Guangzhou,
- Haikou,
- Kunming,
- Nanchang,
- Nanjing,
- Shanghai,
- Shanghai,
- Shanghai,
- Shanghai,
- Xi'An,
- Xi'An,
- Xuzhou,
- Yangzhou,
- Yinchuan,
- Bogota,
- Bogota,
- Bogota,
- Medelin,
- Bamberg,
- Berlin,
- Berlin,
- Berlin,
- Berlin,
- Berlin,
- Frankfurt,
- Hamburg,
- Koblenz,
- Lübeck,
- Rüdersdorf,
- Wiesbaden,
- Witten,
- Ahmedabad,
- Coimbatore,
- Hyderabad,
- Jaipur,
- Jaipur,
- Mumbai,
- Mysore,
- Nagpur,
- Aira, Kagoshima,
- Chuo-ku, Tokyo,
- Fukuoka, Fukuoka,
- Fukuoka, Fukuoka,
- Fukuyama, Hiroshima,
- Habikino, Osaka,
- Hiroshima, Hiroshima,
- Itabashi-ku, Tokyo,
- Iwata, Shizuoka,
- Kanazawa, Ishikawa,
- Kishiwada, Osaka,
- Kitakyushu, Fukuoka,
- Kobe, Hyogo,
- Koto-ku, Tokyo,
- Kyoto, Kyoto,
- Matsusaka, Mie,
- Meguro-ku, Tokyo,
- Minato-ku, Tokyo,
- Minato-ku, Tokyo,
- Morioka, Iwate,
- Naka-gun, Ibaraki,
- Nakano-ku,Tokyo,
- Oita,Oita,
- Osaka-Sayama, Osaka,
- Sapporo, Hokkaido,
- Sendai, Miyagi,
- Seto, Aichi,
- Shinagawa-ku, Tokyo,
- Shizuoka, Shizuoka,
- Toyota, Aichi,
- Urasoe, Okinawa,
- Urasoe, Okinawa,
- Urasoe, Okinawa,
- Yokohama, Kanagawa,
- Yotsukaido, Chiba,
- Mexico City,
- Mexico City,
- Monterrey,
- Lima,
- Lima,
- Lima,
- Lima,
- Lima,
- Bialystok,
- Bydgoszcz,
- Gorzow Wielkopolski,
- Krakow,
- Poznan,
- Sopot,
- Wloszczowa,
- Wroclaw,
- Brasov,
- Brasov,
- Bucharest,
- Bucharest,
- Bucharest,
- Bucharest,
- Bucharest,
- Bucuresti,
- Constanta,
- Iasi,
- Denver, Colorado
- Columbia, Missouri
- Warrensburg, Missouri
- Boys Town, Nebraska
- Canton, Ohio
- Koblenz,
- Rosenheim,
- Wesel,
- Balvi,
- Daugavpils,
- Rezekne,
- Riga,
- Riga,
- Vilnius,
- Vilnius,
- Vilnius,
- Kamnik,
- Ljubljana,
- Maribor,
- Hallein,
- Linz,
- Neumarkt am Wallersee,
- Schlüsslberg,
- Thalheim bei Wels,
- Berlin,
- Berlin,
- Frankfurt,
- Hamburg,
- Hannover,
- Mainz,
- Schwerin,
- Wiesbaden,
- Wiesloch,
- Ivano-Frankivsk,
- Kharkiv,
- Kharkiv,
- Kiev,
- Kiev,
Descriptive Information | ||||
---|---|---|---|---|
Brief Title ICMJE | Study Evaluating the Effect of IMA-026 on Allergen-Induced Late Asthma Response in Mild Asthma | |||
Official Title ICMJE | The Effects of IMA-026 on Allergen-Induced Airway Responses and Airway Inflammation in Subjects With Mild Atopic Asthma | |||
Brief Summary | The purpose of this study is to evaluate the effect of IMA-026, an antibody to IL-13, on airway hyperresponsiveness and airway inflammation in mild asthmatics. IMA-026 will be given as 2 injections under the skin 1 week apart at 2 mg/kg each dose. The study will include a screening period and a treatment period which includes doses on day 1 and day 8. | |||
Detailed Description | Not Provided | |||
Study Type ICMJE | Interventional | |||
Study Phase ICMJE | Phase 1 | |||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Triple (Participant, Care Provider, Investigator) Primary Purpose: Treatment | |||
Condition ICMJE | Asthma | |||
Intervention ICMJE |
| |||
Study Arms ICMJE |
| |||
Publications * | Gauvreau GM, Boulet LP, Cockcroft DW, Fitzgerald JM, Carlsten C, Davis BE, Deschesnes F, Duong M, Durn BL, Howie KJ, Hui L, Kasaian MT, Killian KJ, Strinich TX, Watson RM, Y N, Zhou S, Raible D, O'Byrne PM. Effects of interleukin-13 blockade on allergen-induced airway responses in mild atopic asthma. Am J Respir Crit Care Med. 2011 Apr 15;183(8):1007-14. doi: 10.1164/rccm.201008-1210OC. Epub 2010 Nov 5. | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
Recruitment Information | ||||
Recruitment Status ICMJE | Completed | |||
Estimated Enrollment ICMJE | 24 | |||
Original Estimated Enrollment ICMJE | Same as current | |||
Actual Study Completion Date ICMJE | June 2009 | |||
Actual Primary Completion Date | June 2009 (Final data collection date for primary outcome measure) | |||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| |||
Sex/Gender ICMJE |
| |||
Ages ICMJE | 18 Years to 60 Years (Adult) | |||
Accepts Healthy Volunteers ICMJE | No | |||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
Listed Location Countries ICMJE | Not Provided | |||
Removed Location Countries | ||||
Administrative Information | ||||
NCT Number ICMJE | NCT00725582 | |||
Other Study ID Numbers ICMJE | 3192K1-1002 | |||
Has Data Monitoring Committee | No | |||
U.S. FDA-regulated Product | Not Provided | |||
IPD Sharing Statement ICMJE | Not Provided | |||
Responsible Party | Wyeth (Registry Contact: Clinical Trial Registry Specialist), Wyeth | |||
Study Sponsor ICMJE | Wyeth is now a wholly owned subsidiary of Pfizer | |||
Collaborators ICMJE | Not Provided | |||
Investigators ICMJE |
| |||
PRS Account | Wyeth is now a wholly owned subsidiary of Pfizer | |||
Verification Date | June 2009 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |